# Cerebrolysin

Cerebrolysin has 37 registered human trials. It is marketed for 4 different uses.

**In short**

- 37 registered human trials exist for Cerebrolysin.
- Cerebrolysin is not FDA-approved for any use.
- What has actually been studied: acute cerebral stroke within 12 hours for the first time, stroke, cognitive impairment.
- Last checked against ClinicalTrials.gov on 2026-07-27.

## What it is sold for

- Cognitive enhancement
- Brain recovery
- Neuroprotection
- Anti-aging

## What has actually been tested

- Acute Cerebral Stroke Within 12 Hours for the First Time
- Stroke
- Cognitive Impairment
- Infant Development
- Cerebral Palsy
- Preterm Infant
- Hypoxic-Ischemic Encephalopathy
- Subarachnoid Hemorrhage
- Intracranial Aneurysm
- Delayed Cerebral Ischemia
- Delayed Ischemic Neurological Deficit
- Stroke, Ischemic
- Stroke, Acute
- Stroke Sequelae
- Disorder of Consciousness
- Hemorrhagic Stroke
- Basilar Artery Occlusion
- Posterior Circulation Brain Infarction
- Intracerebral Hemorrhage
- Hemorrhagic Stroke, Intracerebral
- Down Syndrome
- Ischemic Stroke
- Post-covid-19 Persistent Smell and Taste Disorders
- Acute Ischemic Stroke
- Hair Problems
- Neurocognitive Disorders
- Surgery-Complications
- Critical Illness
- Brain Damage
- Cardiac Disease
- Cerebral Palsy Children
- Children With Traumatic Brain Injury
- Mental Handicap
- Delayed Speech Development
- Ischemic Stroke, Acute
- Diabetes Mellitus, Type 2
- Blood Brain Barrier
- Cerebrolysin
- Stroke, Acute, Ischemic
- Vascular Dementia
- Cadasil
- Traumatic Brain Injury
- Rehabilitation Outcome
- Alzheimer Disease
- Chronic Stroke
- Subacute Stroke
- Covid19 Related Anosmia and Aguesia
- Bell Palsy

## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT02149875](https://clinicaltrials.gov/study/NCT02149875) | Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke | Acute Cerebral Stroke Within 12 Hours for the First Time | Phase 2 | COMPLETED | 84 |
| [NCT04913831](https://clinicaltrials.gov/study/NCT04913831) | Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study | Stroke | Phase 4 | UNKNOWN | 30 |
| [NCT06677502](https://clinicaltrials.gov/study/NCT06677502) | Cerebrolysin in Critically Ill Patients With Delirium | Cognitive Impairment | Not phased | ENROLLING_BY_INVITATION | 500 |
| [NCT03506841](https://clinicaltrials.gov/study/NCT03506841) | Cerebrolysin and Neurodevelopment in Preterm Infants | Infant Development, Cerebral Palsy | Phase 1 | COMPLETED | 60 |
| [NCT01388738](https://clinicaltrials.gov/study/NCT01388738) | Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. | Stroke | Phase 3 | COMPLETED | 30 |
| [NCT01059461](https://clinicaltrials.gov/study/NCT01059461) | Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy | Hypoxic-Ischemic Encephalopathy | Phase 2 | COMPLETED | 40 |
| [NCT01787123](https://clinicaltrials.gov/study/NCT01787123) | Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage | Subarachnoid Hemorrhage, Intracranial Aneurysm | Phase 3 | COMPLETED | 50 |
| [NCT04904341](https://clinicaltrials.gov/study/NCT04904341) | Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke. | Stroke, Ischemic, Stroke, Acute | Phase 3 | UNKNOWN | 50 |
| [NCT04427241](https://clinicaltrials.gov/study/NCT04427241) | Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness | Disorder of Consciousness, Hemorrhagic Stroke | Phase 4 | RECRUITING | 12 |
| [NCT06489925](https://clinicaltrials.gov/study/NCT06489925) | Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion | Basilar Artery Occlusion, Posterior Circulation Brain Infarction | Phase 1 | NOT_YET_RECRUITING | 20 |
| [NCT06899464](https://clinicaltrials.gov/study/NCT06899464) | Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial | Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral | Phase 4 | NOT_YET_RECRUITING | 30 |
| [NCT04751136](https://clinicaltrials.gov/study/NCT04751136) | the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome | Down Syndrome | Phase 2 | COMPLETED | 64 |
| [NCT00868283](https://clinicaltrials.gov/study/NCT00868283) | The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke | Ischemic Stroke | Phase 4 | COMPLETED | 1071 |
| [NCT06208540](https://clinicaltrials.gov/study/NCT06208540) | Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants | Post-covid-19 Persistent Smell and Taste Disorders | Phase 4 | COMPLETED | 160 |
| [NCT06078215](https://clinicaltrials.gov/study/NCT06078215) | CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke | Acute Ischemic Stroke | Phase 4 | UNKNOWN | 350 |
| [NCT02768571](https://clinicaltrials.gov/study/NCT02768571) | Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke | Stroke | Phase 4 | COMPLETED | 80 |
| [NCT02581371](https://clinicaltrials.gov/study/NCT02581371) | Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm | Ischemic Stroke | Phase 4 | UNKNOWN | 30 |
| [NCT06897176](https://clinicaltrials.gov/study/NCT06897176) | Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study | Stroke | Phase 4 | RECRUITING | 40 |
| [NCT05288465](https://clinicaltrials.gov/study/NCT05288465) | Hair Repigmentation During Cerebrolysin Therapy | Hair Problems | Not phased | COMPLETED | 5 |
| [NCT06339411](https://clinicaltrials.gov/study/NCT06339411) | Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights | Acute Ischemic Stroke | Phase 1 | NOT_YET_RECRUITING | 100 |
| [NCT00840671](https://clinicaltrials.gov/study/NCT00840671) | Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke | Stroke | Phase 3 | COMPLETED | 119 |
| [NCT05864677](https://clinicaltrials.gov/study/NCT05864677) | Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery | Neurocognitive Disorders, Surgery-Complications | Not phased | UNKNOWN | 100 |
| [NCT02116348](https://clinicaltrials.gov/study/NCT02116348) | Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy | Cerebral Palsy Children, Children With Traumatic Brain Injury | Phase 2 | UNKNOWN | 100 |
| [NCT06273020](https://clinicaltrials.gov/study/NCT06273020) | Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke | Ischemic Stroke, Acute, Diabetes Mellitus, Type 2 | Phase 4 | UNKNOWN | 60 |
| [NCT01996761](https://clinicaltrials.gov/study/NCT01996761) | Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke | Cerebrolysin | Phase 4 | COMPLETED | 71 |
| [NCT05124353](https://clinicaltrials.gov/study/NCT05124353) | Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT | Stroke, Acute, Ischemic | Phase 3 | UNKNOWN | 100 |
| [NCT00947531](https://clinicaltrials.gov/study/NCT00947531) | A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia | Vascular Dementia | Phase 4 | COMPLETED | 242 |
| [NCT05755997](https://clinicaltrials.gov/study/NCT05755997) | CERebrolysin In CADASIL | Cadasil | Phase 2 | ACTIVE_NOT_RECRUITING | 30 |
| [NCT06052787](https://clinicaltrials.gov/study/NCT06052787) | Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU | Traumatic Brain Injury | Phase 3 | COMPLETED | 150 |
| [NCT07043686](https://clinicaltrials.gov/study/NCT07043686) | Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study | Ischemic Stroke, Acute, Rehabilitation Outcome | Not phased | RECRUITING | 30 |
| [NCT01606111](https://clinicaltrials.gov/study/NCT01606111) | The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery | Traumatic Brain Injury | Phase 4 | TERMINATED | 46 |
| [NCT00911807](https://clinicaltrials.gov/study/NCT00911807) | Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease | Alzheimer Disease | Phase 2 | COMPLETED | 217 |
| [NCT01822951](https://clinicaltrials.gov/study/NCT01822951) | Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) | Alzheimer Disease | Phase 4 | WITHDRAWN | 0 |
| [NCT04124367](https://clinicaltrials.gov/study/NCT04124367) | IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE | Chronic Stroke, Subacute Stroke | Phase 2 | TERMINATED | 4 |
| [NCT06070753](https://clinicaltrials.gov/study/NCT06070753) | A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT) | Acute Ischemic Stroke | Not phased | UNKNOWN | 30 |
| [NCT04830943](https://clinicaltrials.gov/study/NCT04830943) | Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia | Covid19 Related Anosmia and Aguesia | Phase 3 | COMPLETED | 250 |
| [NCT05821075](https://clinicaltrials.gov/study/NCT05821075) | Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy | Bell Palsy | Phase 2 | RECRUITING | 90 |

## Common questions

**How many human trials does Cerebrolysin have?**
37, each listed above with a link to its original record.

**Is Cerebrolysin FDA approved?**
No. It is not approved by the FDA for any indication.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/cerebrolysin*